EP2350664
TREATMENT OF CANCER USING THE HYPOXIA ACTIVATED PRODRUG TH-302 IN COMBINATION WITH DOCETAXEL OR PEMETREXED
Status:
EP einkaleyfi: Þýðing ekki lögð innEP appl. date:
21.10.2009EP published:
19.5.2021EP application number:
09822657.4
EPO information:
European Patent Register
Max expiry date:
20.10.2029
Title:
TREATMENT OF CANCER USING THE HYPOXIA ACTIVATED PRODRUG TH-302 IN COMBINATION WITH DOCETAXEL OR PEMETREXED
Timeline
Today
21.10.2009EP application
19.5.2021EP Publication
Owner
Name:
ImmunoGenesis, Inc.Address:
909 Fannin St Suite 2000, Houston TX 77010, US
Inventor
Name:
CURD, John G.Address:
Burlingame California 94010, US
Name:
KROLL, StewartAddress:
Oakland California 94618, US
Name:
MATTEUCCI, MarkAddress:
Portola Valley California 94028, US
Name:
HART, Charles P.Address:
Mountain View California 94040, US
Name:
DUAN, Jian-XinAddress:
Foster City, CA 94404, US
Name:
SUN, Jessica D.Address:
Fremont, CA 94539, US
Priority
Number:
107253 PDate:
21.10.2008Country:
US
Number:
118368 PDate:
26.11.2008Country:
US
Number:
150700 PDate:
6.2.2009Country:
US
Number:
151163 PDate:
9.2.2009Country:
US
Number:
244172 PDate:
21.9.2009Country:
US
Classification
Categories:
A61K 31/337, A61K 31/4985, A61K 31/513, A61K 31/519, A61K 31/555, A61K 31/675, A61K 31/704, A61K 31/7068, A61P 35/00, A61K 9/00, A61P 1/00, A61P 1/18, A61P 13/08, A61P 17/00, A61P 43/00, A61K 45/06, A61K 47/26, A61K 33/24